Do you have triple negative breast cancer? Have you had surgery following chemotherapy? You may be able to participate in a study to find out if stopping pembrolizumab infusions after surgery is just as effective at reducing your risk of cancer recurrence.

Are you between the ages of 40 and 75? Are you willing to give a one-time blood sample? If so, you may be able to take part in a research study that is being used to develop and validate blood tests for early cancer detection.

Do you have stage 1, HER2-positive breast cancer? Has your surgery already been completed? If so, you may be able to take part in a study to help us learn more about a combination of medications to treat your cancer.

Do you have metastatic or recurrent lung cancer? Have you already been treated with chemotherapy or immunotherapy? If so, you may qualify for the LungMap protocol, which will help us identify clinical trials you may be eligible for.

Purpose: Is the combination of T-DM1 and a newer drug tucatinib, better than usual treatment with T-DM1 alone at preventing your cancer from returning? Treatment with T-DM1 and placebo or T-DM1 and tucatinib, for up to 14 cycles, unless the breast cancer returns or the side effects become too severe. If the breast cancer returns while on the study, the treatment will be changed. After completion of T-DM1 and/or placebo, or T-DM1 and tucatinib, the study doctor will continue to follow the patients condition with clinic visits every 6 months for 10 years and watch for side effects and for signs of breast cancer returning.

In this study, we want to learn if decreasing or increasing your radiation and hormonal therapy has an effect on high risk prostate cancer.

Have you been diagnosed with high-risk early triple-negative breast cancer (TNBC) without mutations in the BRCA1 or BRCA2 gene? If you still have evidence of TNBC in your breast or lymph node tissue after receiving treatment and surgery, you may qualify for this clinical research study. This study will test an experimental drug combination to find out which treatment is better at delaying the return of cancer.

This is a Phase III study to help us improve outcomes of patients with ER+/HER2- early breast cancer with intermediate or high risk for disease recurrence. This study is for patients who have completed definitive locoregional therapy and standard adjuvant endocrine therapy for at least 2 years and up to 5 years without disease recurrence. In this study, we want to learn if a new oral "SERD" therapy called Camizestrant is helpful in reducing chance of recurrence. Talk to your Medical Oncologist for more information about this trial.